Dr. Robert E. Federici, MD

Dr. Federici practices at Presbyterian Hospital in Albuquerque, New Mexico, part of Presbyterian Healthcare Services.

Dr. Federici's NPI, 1053315390, was assigned on June 1, 2005. Dr. Federici graduated from Georgetown University School of Medicine in 1988. Dr. Federici holds New Mexico license 96-240.

Dr. Federici's primary practice is Presbyterian Hospital, at 1100 Central Avenue SE, Albuquerque, NM 87106 in Bernalillo County. The practice phone is (505) 724-8386.

Dr. Federici's primary practice is Presbyterian Hospital in Albuquerque, New Mexico, part of Presbyterian Healthcare Services. Dr. Federici is also affiliated with Presbyterian Santa Fe Medical Center. The medical group on file is Presbyterian Medical Group. Dmand AI also links Dr. Federici to 3 more hospitals, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Federici practices, 5 sites in all. Vendor and product names are available with a free account.

Interventional cardiology is Dr. Federici's primary specialty in the NPI Registry, under taxonomy code 207RI0011X. Dr. Federici is board certified in cardiovascular disease by the American Board of Internal Medicine. Dr. Federici is licensed in New Mexico.

CMS data shows 632 Medicare services from Dr. Federici across 12 procedure codes in 2024, for 458 Medicare patients. Medicare paid $40,925 for them.

CMS counts 458 Medicare patients who saw Dr. Federici in 2024. The largest group is 65 to 74, with 166 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 19% are also on Medicaid. Their average risk score is 1.66, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Federici's median patient age at 61, with 52% women.

In 2024, Dr. Federici wrote 1,818 Medicare Part D claims for 305 patients. 87% of them were for generic drugs. CMS names the drug for 1,629 of them, across 27 drugs with 11 or more claims each, at $208,427 in total drug cost. In 2023, CMS named 1,502 claims across 27 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Federici for performance year 2024, reported as part of a group. Dr. Federici accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Federici as offering telehealth. CMS counts 22 procedures of coronary angioplasty and stenting by Dr. Federici, more than 53% of the clinicians it reports for that procedure.

Dmand AI links 9 papers to Dr. Federici, published from 2012 to 2021. 2017 was the busiest year, with 2. The most frequent topics are Coronary Occlusion, Percutaneous Coronary Intervention and Health Status. Dr. Federici has published most often in Catheter Cardiovasc Interv. Dr. Federici's most frequent co-authors are William Louis Lombardi, MD, Jeffrey Warren Moses, MD and William J. Nicholson, MD.

CMS Open Payments shows 670 general payments to Dr. Federici from 33 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 44% of the total. Boston Scientific Corporation paid the most, $106,105.

Dr. Federici graduated from Georgetown University School of Medicine in 1988.